Potential Effects of a Plasticizer on Dyslipidemia and Atherosclerosis
Official title: The Potential Effects of a Universal Plasticizer Alkylsulfonic Phenyl Ester on Dyslipidemia and Atherosclerosis
Funded at University of Nebraska Kearney · NIH-11422558 · Data updated 2026-11-12
A study in young models looks at how certain plastic chemicals might influence cholesterol and artery disease through a key liver receptor.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Kearney NIH-funded |
| Lab location | 1 site (Kearney, United States) |
| Project start | July 27, 2026 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $132,735 |
| NIH project number | 1R16GM159691-01A1 |
| Project ID | NIH-11422558 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal participants would be individuals or communities concerned about environmental exposures affecting lipid health and cardiovascular risk, including families with high exposure to plastic-related chemicals.
✕Less likely to help
Direct patient benefit is unlikely for individuals; findings will more likely influence future public health recommendations and exposures guidelines.
What this research studies
This project examines how plastic-derived chemicals can affect lipid balance and the development of atherosclerosis, focusing on the pregnane X receptor pathway. Using animal models, the researchers will explore mechanisms by which environmental plasticizers may increase cardiovascular risk. The work aims to clarify how exposure translates to changes in arterial health and fatty streak formation, informing future prevention strategies. Results could guide safer plastic use and public health policies to reduce cardiovascular risk associated with environmental exposures.
Why it matters
Potential benefit: If successful, this research could help reduce heart disease risk by identifying environmental factors and informing prevention strategies for at-risk populations.
How similar studies have gone: Prior work has suggested links between plasticizers, liver metabolism, and vascular risk in animal models, but the exact human relevance is still being defined.
Where this research is happening
-
University of Nebraska Kearney
Kearney, United States Active
Researchers
- Principal investigator: Sui, Yipeng — University of Nebraska Kearney
- Study coordinator: Sui, Yipeng
Related research
Other NIH-funded projects on the same topics.
-
Fabkin, a New Hormone Complex, and Its Role in Lipids and Inflammation Driving Atherosclerosis
A new hormone complex called Fabkin is being studied to see if it links fat metabolism and inflammation in atherosclerosis so future treatments could target both problems.
-
Investigating the role of APOC3 in heart and kidney diseases related to diabetes
This study is looking at how a protein called APOC3 affects heart and kidney problems in people with diabetes, and it hopes to find out if blocking this protein can help prevent kidney disease, especially in those with both diabetes and kidney issues, which might raise the risk of heart disease.
-
How air pollution affects cholesterol levels and heart disease through gut bacteria
This study is looking at how breathing in tiny air pollution particles might affect your cholesterol and heart health by changing the bacteria in your gut, and it aims to find new ways to help people at risk for heart problems due to air pollution.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
PFAS may speed up artery disease by changing bile acids
Aims to see if PFAS chemicals make cholesterol rise and arteries more likely to harden, using a human-similar mouse model to understand how this could affect people.
-
IgE antibodies to alpha-gal and heart disease in mice and people
A study to understand how specific IgE antibodies against alpha-gal might influence the development and severity of atherosclerosis in humans and mouse models.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.